Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - Greenlite Ventures Inc. - Exhibit 10.5

MANAGEMENT CONSULTANT AGREEMENT

THIS MANAGEMENT CONSULTANT AGREEMENT (the "Agreement")
is made and entered into effective as of the 16th day of February, 2008
(the "Effective Date"), 

BETWEEN:

GREENLITE VENTURES INC., a
Nevada corporation, having a corporate office at Suite 201, 810 Peace Portal
Drive, Blaine, WA 98230

(the "Company") 

     OF THE FIRST PART 

and 

HOWARD THOMSON of Brookside,
Ballymabin, Dunmore East, County Waterford, Ireland

(the “Consultant”).

OF THE SECOND PART

WHEREAS:

A. The Company is engaged in the business of mineral
exploration.

B. The Company desires to retain the Consultant to act as
President, Chief Executive Officer, Chief Financial Officer, Secretary and
Treasurer of the Company and to provide consultant services to the Company on
the terms and subject to the conditions of this Agreement.

C. The Consultant has agreed to act as President, Chief
Executive Officer, Chief Financial Officer, Secretary and Treasurer of the
Company and to provide consultant services to the Company on the terms and
subject to the conditions of this Agreement.

THIS AGREEMENT WITNESSES THAT in consideration of the
premises and mutual covenants contained in this Agreement and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties, intending to be legally bound hereby, agree as
follows:

1. DEFINITIONS

1.1 The following terms used in this Agreement shall have the
meaning specified below unless the context clearly indicates the contrary:

	 	(a) 	
      "Consultant Fee" shall mean the consultant fee
      payable to the Consultant at the rate set forth in Section 5.1;

	 	 	 
	 	(b) 	
      "Board" shall mean the Board of Directors of the
      Company;

	 	 	 
	 	(c) 	
      "Term" shall mean the term of this Agreement
      beginning on the Effective Date and ending on the close of business on the
      date of the termination of this Agreement.

2

2. ENGAGEMENT AS A CONSULTANT

2.1 The Company hereby engages the Consultant as a consultant
to provide the services of the Consultant in accordance with the terms and
conditions of this Agreement and the Consultant hereby accepts such
engagement.

3. TERM OF THIS AGREEMENT

3.1 The term of this Agreement shall become effective and begin
as of the Effective Date, and shall continue until two years from the Effective
Date at the close of business, unless this Agreement is earlier terminated in
accordance with the terms of this Agreement or extended by the Board of
Directors of the Company.

4. CONSULTANT SERVICES

4.1 The Consultant agrees to act as the President, Chief
Executive Officer, Chief Financial Officer, Secretary and Treasurer of the
Company and to perform the following services and undertake the following
responsibilities and duties to the Company as consulting services (the
"Consulting Services"):

	 	(a) 	
      exercising general direction and supervision over the
      business and financial affairs of the Company;

	 	 	 
	 	(b) 	
      providing overall direction to the management of the
      Company;

	 	 	 
	 	(c) 	
      reporting directly to board of directors of Company;
      and

	 	 	 
	 	(d) 	
      performing such other duties and observing such
      instructions as may be reasonably assigned from time to time by or on
      behalf of the board of directors of the Company in the Consultant’s
      capacity as President, Chief Executive Officer, Chief Financial Officer,
      Secretary and Treasurer, provided such duties are within the scope of the
      Company’s business and implementation of the Company’s business
    plan.

4.2 The Consultant shall devote such attention and energies to
the business affairs of the Company as may be reasonably necessary for the
discharge of his duties as President, Chief Executive Officer, Chief Financial
Officer, Secretary and Treasurer, provided, however, the Consultant may engage
in reasonable investment and other personal activities that do not interfere
with the Consultant's obligations hereunder. 

4.3 The Consultant will at all times be an independent
contractor and the Consultant will not be deemed to be an employee of the
Company.

5. CONSULTANT FEE

5.1 During the term of this Agreement, the Company shall pay
the Consultant a consultant fee in consideration of the provision of the
Consulting Services equal to $750 US per month (the "Consultant Fee").

3

6. STOCK OPTIONS

6.1 The Consultant may be granted, subject to the approval of
the Company’s board of directors, incentive stock options to purchase shares of
the Company’s common stock in such amounts and at such times as the Board of
Directors of the Company, in their absolute discretion, may from time to time
determine.

7. REIMBURSEMENT OF EXPENSES

7.1 The Company will pay to the Consultant, in addition to the
Consultant Fee, the reasonable travel and promotional expenses and other
specific expenses incurred by the Consultant in provision of the Consulting
Services, provided the Consultant has obtained the prior written approval of the
Company. 

8. TERMINATION

8.1 The Company may terminate this Agreement: (i) at any time
on three (3) months’ notice; or (ii) without notice upon the occurrence of any
of the following events of default (each an “Event of Default”):

	 	(a) 	
      the Consultant’s commission of an act of fraud, theft or
      embezzlement or other similar willful misconduct;

	 	 	 
	 	(b) 	
      the neglect or breach by the Consultant of his material
      obligations or agreements under this Agreement; or

	 	 	 
	 	(c) 	
      the Consultant’s refusal to follow lawful directives of
      the Board,

provided that notice of the Event of Default has been delivered
to the Consultant and provided the Consultant has failed to remedy the default
within thirty (30) days of the date of delivery of notice of the Event of
Default.

8.2 The Consultant may terminate this Agreement at any time
upon thirty (30) days’ notice.

8.3 On termination of this Agreement for any reason, all rights
and obligations of each party that are expressly stated to survive termination
or continue after termination will survive termination and continue in full
force and effect as contemplated in this Agreement.

9. PROPRIETARY INFORMATION AND DEVELOPMENTS

9.1 The Consultant will not at any time, whether during or
after the termination of this Agreement for any reason, reveal to any person or
entity any of the trade secrets or confidential information concerning the
organization, business or finances of the Company or of any third party which
the Company is under an obligation to keep confidential, except as may be
required in the ordinary course of performing the Consultant Services to the
Company, and the Consultant shall keep secret such trade secrets and
confidential information and shall not use or attempt to use any such secrets or
information in any manner which is designed to injure or cause loss to the
Company. Trade secrets or confidential information shall include, but not be
limited to, the Company's financial statements and projections, expansion
proposals, property acquisition opportunities and business relationships with
banks, lenders and other parties not otherwise publicly available.

4

10. RELIEF

10.1 The Consultant hereby expressly acknowledges that any
breach or threatened breach by the Consultant of any of the terms set forth in
Section 9 of this Agreement may result in significant and continuing injury to
the Company, the monetary value of which would be impossible to establish, and
any such breach or threatened breach will provide the Company with any and all
rights and remedies to which it may be entitled under the law, including but not
limited to injunctive relief or other equitable remedies.

11. PARTIES BENEFITED; ASSIGNMENTS

11.1 This Agreement shall be binding upon, and inure to the
benefit of, the Consultant, his heirs and his personal representative or
representatives, and upon the Company and its successors and assigns. Neither
this Agreement nor any rights or obligations hereunder may be assigned by the
Consultant.

12. NOTICES

12.1 Any notice required or permitted by this Agreement shall
be in writing, sent by registered or certified mail, return receipt requested,
or by overnight courier, addressed to the Board and the Company at its then
principal office, or to the Consultant at the address set forth in the preamble,
as the case may be, or to such other address or addresses as any party hereto
may from time to time specify in writing for the purpose in a notice given to
the other parties in compliance with this Section 12. Notices shall be deemed
given when delivered.

13. GOVERNING LAW

13.1 This Agreement shall be governed by and construed in
accordance with the laws of the State of Nevada and each party hereto adjourns
to the jurisdiction of the courts of the State of Nevada. 

14. REPRESENTATIONS AND WARRANTIES

14.1 The Consultant represents and warrants to the Company that
(a) the Consultant is under no contractual or other restriction which is
inconsistent with the execution of this Agreement, the performance of his duties
hereunder or other rights of Company hereunder, and (b) the Consultant is under
no physical or mental disability that would hinder the performance of his duties
under this Agreement.

15. MISCELLANEOUS

15.1 This Agreement contains the entire agreement of the
parties relating to the subject matter hereof. 

15.2 This Agreement supersedes any prior written or oral
agreements or understandings between the parties relating to the subject matter
hereof.

15.3 No modification or amendment of this Agreement shall be
valid unless in writing and signed by or on behalf of the parties hereto.

15.4 A waiver of the breach of any term or condition of this
Agreement shall not be deemed to constitute a waiver of any subsequent breach of
the same or any other term or condition. 

5

15.5 This Agreement is intended to be performed in accordance
with, and only to the extent permitted by, all applicable laws, ordinances,
rules and regulations. If any provision of this Agreement, or the application
thereof to any person or circumstance, shall, for any reason and to any extent,
be held invalid or unenforceable, such invalidity and unenforceability shall not
affect the remaining provisions hereof and the application of such provisions to
other persons or circumstances, all of which shall be enforced to the greatest
extent permitted by law. 

15.6 The headings in this Agreement are inserted for
convenience of reference only and shall not be a part of or control or affect
the meaning of any provision hereof.

15.7 The Consultant acknowledges and agrees that O'Neill Law
Group PLLC has acted solely as legal counsel for the Company and that the
Consultant has been advised to obtain independent legal advice prior to
execution of this Agreement.

15.8 This Agreement may be executed in one or more
counter-parts, each of which so executed shall constitute an original and all of
which together shall constitute one and the same agreement.

IN WITNESS WHEREOF, the parties have duly executed and
delivered this Agreement as of the date first written above.

GREENLITE VENTURES INC. by its authorized signatory:

	/s/ Howard
      Thomson 	 	  
	HOWARD THOMSON, DIRECTOR 	 	  
	  	 	  
	SIGNED, SEALED AND DELIVERED 	 	  
	BY HOWARD THOMSON in the presence of: 	 	  
	  	 	  
	/s/ Charles
      Hethey 	 	/s/
      Howard Thomson 
	Signature 	 	HOWARD THOMSON 
	  	 	  
	Charles Hethey 	 	  
	Name 	 	  
	  	 	  
	950-650 W. Georgia
    	 	  
	Address 	 	  
	  	 	  
	Vancouver, BCexhibit1051_ghspurchagt.htm

    Exhibit
      10.51

    
 

    COMMON
      STOCK PURCHASE AGREEMENT

     

    This
      Common Stock Purchase Agreement (the “Agreement”) is made as of February
      8, 2008, by and between Cytori Therapeutics, Inc., a Delaware corporation (the
      “Company”), and Green Hospital Supply, Inc., located at 3-20-8 Kasuga
      Suita-City, Osaka 565-0853, Japan (“Purchaser”).

     

    1.           Sale
      of Stock.  Subject to the terms and
      conditions of this Agreement, the Company will issue and sell to Purchaser,
      and
      Purchaser agrees to purchase from the Company, two million
      (2,000,000)  unregistered shares of the Company’s Common Stock (the
“Shares”) at a purchase price of US $6.00 per Share for a total of US
      $12,000,000. (“Purchase Price”).

     

    2.           Purchase.  The
      purchase and sale of the Shares under Section 1 of this Agreement shall occur
      at
      a closing at the principal office of the Company within 14 days of the execution
      of this Agreement by the parties.  At the closing, the Company shall
      deliver the Shares into the account specified by Purchaser, and Purchaser shall
      immediately deliver the Purchase Price therefor to Company by wire transfer,
      or
      by alternate means agreed between the Parties.  

     

    3.           Limitations
      on Transfer.  Purchaser shall not
      assign, encumber or dispose of any interest in the Shares except in compliance
      with applicable securities laws and regulations of applicable countries and
      stock exchanges.  It is Purchaser's responsibility to familiarize
      itself with such laws and regulations.

     

    4          Company’s
      Representation. The Company hereby represents and warrants to the
      Purchaser as follows:

    

    (a)           The
      Company is duly organized and validly existing under the laws of the State
      of
      Delaware and has all requisite corporate power and authority to enter into
      this
      Agreement and to consummate the transactions contemplated hereby.

    

    (b)           The
      Company has the right and power to enter into and perform its obligations under
      this Agreement; has taken all necessary corporate actions required to enter
      into
      and perform its obligations under this Agreement; and this Agreement constitutes
      the legal, valid and binding obligation of the Company, enforceable in
      accordance with its terms.

    

    (c)           The
      execution of this Agreement and the consummation of the transactions
      contemplated hereby will not result in a breach of any of the terms or
      provisions of, or constitute a default under, any agreement, or other instrument
      to which the Company is a party or by which it is bound.

    

    (d)           All
      consents, approvals, authorizations and other requirements prescribed by any
      law, rule or regulation which must be obtained or satisfied by the Company
      in
      order to permit the consummation of the transactions contemplated by this
      Agreement have been, or will have been as of the Closing Date, obtained and
      satisfied.

    

    (e)                      The
      authorized capitalization of the Company consists solely of 95,000,000
      authorized shares of common stock, and 5,000,000 shares of preferred
      stock.

    

    (f)           The
      Shares have been duly and validly authorized and reserved for issuance and,
      when
      issued and delivered,  will be duly and validly issued, fully paid and
      non-assessable and will be owned by the Purchaser, free and clear of liens,
      encumbrances, equities or claims.

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    (g)            The
      Company’s latest audited financial statements as of and for the year ended
      December 31, 2006, and latest un-audited financial statements as of and for
      the
      quarter ended September  30, 2007 fairly represent the true financial
      position of the Company in all material respects and in conformity with
      generally accepted accounting principles applied on a consistent
      basis.

    

    5.           Investment
      Representations.  In connection with the
      purchase of the Shares, Purchaser represents to the Company the
      following:

     

    (a)           The
      Company is a reporting company under the U.S. Securities Exchange Act, and
      its
      various periodic reports and other SEC filings are available for public
      inspection on the EDGAR system at www.sec.gov.  Purchaser further
      acknowledges that Purchaser and Purchaser’s advisors have had the opportunity to
      ask questions of and receive answers from the Company’s management concerning
      this investment.  Purchaser is aware of the Company’s business affairs
      and financial condition based on the said public available information and
      the
      answers from the Company’s management (the “Information”) and Purchaser and
      Purchaser’s advisors has evaluated the merits and risks of an investment in the
      Company and decided to acquire the Shares based on such
      Information.

     

    (b)           Purchaser
      understands that the Shares have not been registered under the U.S. Securities
      Act by reason of a specific exemption therefrom, which exemption depends upon,
      among other things, the bona fide nature of Purchaser’s investment intent as
      expressed herein.

     

     (c)           Purchaser
      understands that the Shares are “restricted securities” within the meaning of
      applicable U.S. federal and state securities laws and that, pursuant to these
      laws, Purchaser must hold the Shares indefinitely unless they are registered
      with the U.S. Securities and Exchange Commission and qualified by state
      authorities, or an exemption from such registration and qualification
      requirements is available (e.g., Rule 144 or Regulation S).  Purchaser
      further acknowledges that if an exemption from registration or qualification
      is
      available, it may be conditioned on various requirements including, but not
      limited to, the time and manner of sale, the holding period for the Shares,
      and
      requirements relating to the Company which are outside of the Purchaser’s
      control, and which the Company is under no obligation and may not be able to
      satisfy.

     

    (d)           Purchaser
      is an "accredited investor," as defined in US Securities Act Rule
      501.

     

    (e)           Purchaser
      has not entered into any agreement to pay commissions to any persons with
      respect to the purchase or sale of the Shares, except commissions for which
      Purchaser will be responsible.

     

    (f)           Purchaser
      understands and acknowledges that no Japanese, German or United States federal
      or state agency, governmental authority, regulatory body, stock exchange or
      other entity has made any finding or determination as to the merits of this
      investment, nor have any such agencies, governmental authorities, regulatory
      bodies, stock exchanges or other entities made any recommendation or endorsement
      with respect to the Shares.

     

    (g)           Purchaser,
      in evaluating the merits of an investment in the Shares, is not relying on
      the
      Company, its counsel, or any financial or other advisor to the Company for
      an
      evaluation of the tax, legal or other consequences of an investment in the
      Shares.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    (h)           Purchaser
      is purchasing the Shares for investment for its own account only and not with
      a
      view to, or for resale in connection with, any “distribution” thereof within the
      meaning of the U.S. Securities Act. 

     

    6.           Legends.  The
      certificates overlying the Shares shall bear the following legends:

     

    "The
      shares of common stock of Cytori Therapeutics, Inc. represented hereby have
      not
      been registered under the United States Securities Act of 1933, as amended
      (the
“Securities Act”).  These securities may not be offered, sold, pledged
      or otherwise transferred (nor may exposure with respect to the shares otherwise
      be hedged) except (A)(1) in an offshore transaction complying with Rule 903
      or
      Rule 904 of Regulation S under the Securities Act, (2) pursuant to an exemption
      from registration under the Securities Act provided by Rule 144 thereunder
      (if
      available), or (3) pursuant to another valid exemption from registration under
      the Securities Act (if available), and (B) in each case in accordance with
      all
      applicable securities laws of the States of the United States.  No
      representation can be made as to the availability of the exemption provided
      by Rule 144 under the Securities Act for resales of the shares.

     

    This
      certificate evidences and entitles the holder hereof to certain rights as set
      forth in a Rights Agreement between Cytori Therapeutics, Inc. and Computershare
      Trust Company, Inc., a Colorado corporation, as Rights Agent, dated as of May
      29, 2003, as amended (the "Rights Agreement"), the terms of which are hereby
      incorporated herein by reference and a copy of which is on file at the principal
      executive offices of Cytori Therapeutics, Inc. Under certain circumstances,
      as
      set forth in the Rights Agreement, such rights will be evidenced by separate
      certificates and will no longer be evidenced by this certificate. Cytori
      Therapeutics, Inc. will mail to the holder of this certificate a copy of the
      Rights Agreement without charge after receipt of a written request therefor.
      Under certain circumstances set forth in the Rights Agreement, rights issued
      to,
      or held by, any Person who is, was or becomes an Acquiring Person or an
      Affiliate or Associate thereof (as defined in the Rights Agreement) and certain
      related Persons, whether currently held by or on behalf of such Person or by
      any
      subsequent holder, may become null and void."

     

    7.           Registration.  The
      Company shall within 30 business days after receipt of written request by
      Purchaser use reasonable efforts to, prepare and file with the US Securities
      and
      Exchange Commission (the "Commission") a Registration Statement covering
      the resale of the Shares for an offering to be made on a continuous basis
      pursuant to Rule 415. The Registration Statement shall be on Form S-3 (except
      if
      the Company is not then eligible to register for resale the Shares on Form
      S-3,
      in which case such registration shall be on another appropriate form in
      accordance with the US Securities Act and the rules promulgated
      thereunder).  The Company shall use its reasonable efforts to cause
      the Registration Statement to be declared effective under the US Securities
      Act
      within 60 business days after such filing. The Company shall keep such
      Registration Statement continuously effective under the Securities Act for
      a
      period of two years (the “Effectiveness Period”).

     

     

    8.           Registration
      Procedures; Company’s Obligations.  In
      connection with the obligation for the registration of the Shares above, the
      Company shall: 

     

     (a)           Furnish
      to the Purchaser a copy of the Registration Statement as proposed to be
      filed.

     

     (b)           Prepare
      and file with the Commission such amendments, including post-effective
      amendments, to the Registration Statement as may be necessary to keep the
      Registration Statement continuously effective as to the applicable Shares for
      the Effectiveness Period; (ii) cause the related Prospectus to be amended or
      supplemented by any required Prospectus supplement, and as so supplemented
      or
      amended to be filed pursuant to Rule 424 (or any similar provisions then in
      force) promulgated under the Securities Act; and (iii) respond promptly to
      any
      comments received from the Commission with respect to the Registration Statement
      or any amendment thereto and promptly provide the Purchaser true and complete
      copies of all correspondence from and to the Commission relating to the
      Registration Statement.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    (c)           Notify
      the Purchaser (i)(A) when a Prospectus or any Prospectus supplement or
      post-effective amendment to the Registration Statement is proposed to be filed,
      (B) when the Commission notifies the Company whether there will be a “review” of
      such Registration Statement and whenever the Commission comments in writing
      on
      such Registration Statement, and (C) with respect to the Registration Statement
      or any post-effective amendment, when the same has become effective; (ii) of
      any
      request by the Commission or any other Federal or state governmental authority
      for amendments or supplements to the Registration Statement or Prospectus or
      for
      additional information; (iii) of the issuance by the Commission of any stop
      order suspending the effectiveness of the Registration Statement covering any
      or
      all of the Shares or the initiation of any proceedings for that purpose; (iv)
      of
      the receipt by the Company of any notification with respect to the suspension
      of
      the qualification or exemption from qualification of any of the Shares for
      sale
      in any State of the US, or the initiation or threatening of any proceeding
      for
      such purpose; and (v) of the occurrence of any event that makes any statement
      made in the Registration Statement or Prospectus or any document incorporated
      or
      deemed to be incorporated therein by reference untrue in any material respect
      or
      that requires any revisions to the Registration Statement, Prospectus or other
      documents so that, in the case of the Registration Statement or the Prospectus,
      as the case may be, it will not contain any untrue statement of a material
      fact
      or omit to state any material fact required to be stated therein or necessary
      to
      make the statements therein, in the light of the circumstances under which
      they
      were made, not misleading.

     

     (d)           Use
      its reasonable commercial efforts to avoid the issuance of, or, if issued,
      obtain the withdrawal of, (i) any order suspending the effectiveness of the
      Registration Statement, or (ii) any suspension of the qualification (or
      exemption from qualification) of any of the Shares for sale in any State of
      the
      US, at the earliest practicable moment.

     

     (e)           If
      requested by the Purchaser, (i) promptly incorporate in a Prospectus supplement
      or post-effective amendment to the Registration Statement such information
      as
      the Company reasonably agrees should be included therein, and (ii) make all
      required filings of such Prospectus supplement or such post-effective amendment
      as soon as practicable after the Company has received notification of the
      matters to be incorporated in such Prospectus supplement or post-effective
      amendment.

     

     (f)           Furnish
      to the Purchaser, without charge, at least one conformed copy of the
      Registration Statement and each amendment thereto, including financial
      statements and schedules, all documents incorporated or deemed to be
      incorporated therein by reference, and all exhibits to the extent requested
      by
      such Person (including those previously furnished or incorporated by reference)
      promptly after the filing of such documents with the Commission.

     

     (g)           Promptly
      deliver to the Purchaser, without charge, as many copies of the Registration
      Statement, Prospectus or Prospectuses (including each form of prospectus) and
      each amendment or supplement thereto as Purchaser may reasonably request; and
      the Company hereby consents to the use of such Prospectus and each amendment
      or
      supplement thereto by the Purchaser in connection with the offering and sale
      of
      the Shares covered by such Prospectus and any amendment or supplement thereto.
      Should the Purchaser offer or sell the Shares, such Purchaser agrees to comply
      with all applicable securities laws.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     (h)           Use
      its reasonable commercial efforts to register or qualify or cooperate with
      the
      selling Purchaser in connection with the registration or qualification (or
      exemption from such registration or qualification) of such Shares for offer
      and
      sale under the securities or Blue Sky laws of each State of the US as the
      Purchaser reasonably requests in writing, to keep each such registration or
      qualification (or exemption therefrom) effective during the Effectiveness Period
      and to do any and all other acts or things necessary or advisable to enable
      the
      disposition in such States of the Shares covered by a Registration Statement;
      provided, however, that the Company shall not be required to
      qualify generally to do business in any jurisdiction where it is not then so
      qualified or to take any action that would subject it to general service of
      process in any such jurisdiction where it is not then so subject or subject
      the
      Company to any tax in any such jurisdiction where it is not then so
      subject.

     

     (i)           Upon
      the occurrence of any event contemplated by Section 8(c)(v), promptly prepare
      a
      supplement or amendment, including a post-effective amendment, to the
      Registration Statement or a supplement to the related Prospectus or any document
      incorporated or deemed to be incorporated therein by reference, and file any
      other required document so that, as thereafter delivered, neither the
      Registration Statement nor such Prospectus will contain an untrue statement
      of a
      material fact or omit to state a material fact required to be stated therein
      or
      necessary to make the statements therein, in the light of the circumstances
      under which they were made, not misleading.

     

     (j)           Use
      its reasonable efforts to cause all Shares to be listed on any US national
      securities exchange (such as the NASDAQ Global Market), US quotation system,
      or
      US over-the-counter bulletin board, if any, on which the same securities issued
      by the Company are then listed.

     

     (k)           If
      (i) there is material non-public information regarding the Company which the
      Company’s Board of Directors reasonably determines not to be in the Company’s
      best interest to disclose and which the Company is not otherwise required to
      disclose, or (ii) there is a significant business opportunity (including, but
      not limited to, the acquisition or disposition of assets (other than in the
      ordinary course of business) or any merger, consolidation, tender offer or
      other
      similar transaction) available to the Company which the Company’s Board of
      Directors reasonably determines not to be in the Company’s best interest to
      disclose and which the Company would be required to disclose under the
      Registration Statement, then the Company may suspend effectiveness of the
      Registration Statement and suspend the sale of Shares under the Registration
      Statement one time every three months or three times in any twelve month period,
      provided that the Company may not suspend its obligation for more than 60 days
      in the aggregate in any 12 month period.

     

    9.           Registration
      Procedures; Purchaser’s Obligations.  In connection with
      the registration of the Shares, the Purchaser shall:

     

    (a)           (i)
      not sell any Shares under the Registration Statement until it has received
      copies of the Prospectus as then amended or supplemented as contemplated in
      Section 8(g) and the notice from the Company that such Registration Statement
      and any post-effective amendments thereto have become effective as contemplated
      by Section 8(c), (ii) comply with the prospectus delivery requirements of the
      Securities Act as applicable to it in connection with sales of Shares pursuant
      to the Registration Statement, and (iii) furnish to the Company information
      regarding such Purchaser and the distribution of such Shares as is required
      by
      law to be disclosed in the Registration Statement.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    (b)           upon
      receipt of a notice from the Company of the occurrence of any event of the
      kind
      described in Section 8(c)(ii), 8(c)(iii), 8(c)(iv), 8(c)(v) or 8(k), forthwith
      discontinue disposition of such Shares under the Registration Statement until
      the Purchaser’s receipt of the copies of the supplemented Prospectus and/or
      amended Registration Statement contemplated by Section 8(i), or until it is
      advised in writing by the Company that the use of the applicable Prospectus
      may
      be resumed, and, in either case, has received copies of any additional or
      supplemental filings that are incorporated or deemed to be incorporated by
      reference in such Prospectus or Registration Statement.

     

    10.           Registration
      Expenses.

    

    All
      reasonable fees and expenses incident to the performance of or compliance with
      this Agreement by the Company shall be borne by the Company whether or not
      any
      Shares are sold pursuant to the Registration Statement.

     

    11.           Indemnification.

     

    (a)           Indemnification
      by the Company. The Company shall indemnify and hold harmless Purchaser, its
      permitted assignees, officers, directors, agents, brokers, investment advisors
      and employees, each person who controls Purchaser or a permitted assignee
      (within the meaning of Section 15 of the Securities Act or Section 20 of the
      Exchange Act) and the officers, directors, agents and employees of each such
      controlling person, and the respective successors, assigns, estate and personal
      representatives of each of the foregoing, to the fullest extent permitted by
      applicable law, from and against any and all claims, losses, damages,
      liabilities, penalties, judgments, costs (including, without limitation, costs
      of investigation) and expenses (including, without limitation, reasonable
      attorneys’ fees and expenses) (collectively, “Losses”), as incurred,
      arising out of or relating to any untrue or alleged untrue statement of a
      material fact contained in the Registration Statement, any Prospectus, as
      supplemented or amended, if applicable, or arising out of or relating to any
      omission or alleged omission of a material fact required to be stated therein
      or
      necessary to make the statements therein (in the case of any Prospectus or
      supplement thereto, in the light of the circumstances under which they were
      made) not misleading, except (i) to the extent, but only to the extent, that
      such untrue statements or omissions are based solely upon information regarding
      the Purchaser furnished in writing to the Company by the Purchaser expressly
      for
      use therein, or (ii) as a result of the failure of the Purchaser to deliver
      a
      Prospectus, as amended or supplemented, to a purchaser in connection with an
      offer or sale. The Company shall notify the Purchaser promptly of the
      institution, threat or assertion of any Proceeding of which the Company is
      aware
      in connection with the transactions contemplated by this
      Agreement.  Such indemnity shall remain in full force and effect
      regardless of any investigation made by or on behalf of an Indemnified Party
      (as
      defined in Section 11(b)
      hereof) and shall survive the transfer of the Shares by the
      Purchaser.

     

    (b)           Conduct
      of Indemnification Proceedings. If any Proceeding shall be brought or
      asserted against any Person entitled to indemnity pursuant to Section 11(a)
      hereunder (an “Indemnified Party”), such Indemnified Party promptly shall
      notify the Person from whom indemnity is sought (the “Indemnifying Party)
      in writing, and the Indemnifying Party shall assume the defense thereof,
      including the employment of counsel reasonably satisfactory to the Indemnified
      Party and the payment of all fees and expenses incurred in connection with
      defense thereof; provided, that the failure of any Indemnified Party to
      give such notice shall not relieve the Indemnifying Party of its obligations
      or
      liabilities pursuant to this Agreement, except (and only) to the extent that
      it
      shall be finally determined by a court of competent jurisdiction (which
      determination is not subject to appeal or further review) that such failure
      shall have materially and adversely prejudiced the Indemnifying
      Party.

    
      
         

      

      
        6

        
          

        

      

      
         

    

    An
      Indemnified Party shall have the right to employ separate counsel in any such
      Proceeding and to participate in the defense thereof, but the fees and expenses
      of such counsel shall be at the expense of such Indemnified Party or Parties
      unless: (i) the Indemnifying Party has agreed in writing to pay such fees and
      expenses; or (ii) the Indemnifying Party shall have failed promptly to assume
      the defense of such Proceeding and to employ counsel reasonably satisfactory
      to
      such Indemnified Party in any such Proceeding; or (iii) the named parties to
      any
      such Proceeding (including any impleaded parties) include both such Indemnified
      Party and the Indemnifying Party, and such Indemnified Party shall have been
      advised by counsel that a conflict of interest is likely to exist if the same
      counsel were to represent such Indemnified Party and the Indemnifying Party
      (in
      which case, if such Indemnified Party notifies the Indemnifying Party in writing
      that it elects to employ separate counsel at the expense of the Indemnifying
      Party, the Indemnifying Party shall not have the right to assume the defense
      thereof and such counsel shall be at the expense of the Indemnifying
      Party).  The Indemnifying Party shall not be liable for any settlement
      of any such Proceeding effected without its written consent, which consent
      shall
      not be unreasonably withheld, conditioned or delayed.  No Indemnifying
      Party shall, without the prior written consent of the Indemnified Party, which
      consent shall not unreasonably be withheld, conditioned or delayed, effect
      any
      settlement of any pending Proceeding in respect of which any Indemnified Party
      is a party, unless such settlement includes an unconditional release of such
      Indemnified Party from all liability on claims that are the subject matter
      of
      such Proceeding.

     

    All
      reasonable fees and expenses of the Indemnified Party (including reasonable
      fees
      and expenses to the extent incurred in connection with investigating or
      preparing to defend such Proceeding in a manner not inconsistent with this
      Section) shall be paid to the Indemnified Party, as incurred, within 20 business
      days of written notice thereof to the Indemnifying Party (regardless of whether
      it is ultimately determined that an Indemnified Party is not entitled to
      indemnification hereunder; provided, that the Indemnifying Party may
      require such Indemnified Party to undertake to reimburse all such fees and
      expenses to the extent it is finally judicially determined that such Indemnified
      Party is not entitled to indemnification hereunder or pursuant to applicable
      law).

     

     (c)           The
      indemnity agreement contained in this Section is in addition to any liability
      that the Indemnifying Parties may have to the Indemnified Parties.

     

    12.           No
      Special Rights.  Nothing in this
      Agreement shall affect in any manner whatsoever the right or power of the
      Company to negotiate, or to decline to negotiate, any contractual relationship
      with Purchaser, nor the right or power of Purchaser to negotiate, or to decline
      to negotiate, any contractual relationship with the Company.

     

    13.           Board
      Observer Seat.  So long as Purchaser continues to own all
      of the Shares purchased hereunder or at least 10% of the Company’s outstanding
      shares, the Company shall permit Purchaser to designate one representative
      reasonably acceptable to the Company as a non-voting observer to the Board
      of
      Directors. The Purchaser representative shall receive all notices, documents
      and
      other information supplied to members of the Board of Directors. The Company
      shall allow the representative to observe Board of Directors meetings by
      telephone if they are unable to attend in person. The Purchaser representative
      (and Purchaser) shall hold all information received thereby in strict
      confidentiality, and shall sign a confidentiality agreement provided by the
      Company requiring all information disclosed pursuant to the Board Observer
      Seat
      to be held in complete confidence and trust. The Company reserves the right
      to
      withhold certain information, and/or to exclude the Purchaser representative
      from any meeting or portion thereof, if, in the judgment of the Board of
      Directors the failure to do so might compromise the attorney-client privilege,
      or potentially result in a conflict of interest situation.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    14.           Miscellaneous.

     

    (a)           Governing
      Law.  This Agreement and all acts and
      transactions pursuant hereto and the rights and obligations of the parties
      hereto shall be governed, construed and interpreted in accordance with the
      laws
      of the State of California, without giving effect to principles of conflicts
      of
      law. 

     

     (b)           Entire
      Agreement; Enforcement of Rights.  This
      Agreement sets forth the entire agreement and understanding of the parties
      relating to the subject matter herein and merges all prior discussions between
      them with regard to such subject matter.  No modification of or
      amendment to this Agreement, nor any waiver of any rights under this Agreement,
      shall be effective unless in writing signed by the parties to this
      Agreement.  The failure by either party to enforce any rights under
      this Agreement shall not be construed as a waiver of any rights of such
      party.

     

     (c)           Construction.  This
      Agreement is the result of negotiations between and has been reviewed by both
      of
      the parties hereto and their respective counsel, if any; accordingly, this
      Agreement shall be deemed to be the product of both of the parties hereto,
      and
      no ambiguity shall be construed in favor of or against either one of the parties
      hereto.

     

     (d)           Notices.  Any
      notice required or permitted by this Agreement shall be in writing and shall
      be
      deemed sufficient when delivered personally or sent and confirmed by fax or
      48
      hours after being deposited in the U.S. mail, as certified or registered mail,
      with postage prepaid, and addressed to the party to be notified at such party’s
      address or fax number as set forth below or as subsequently modified by written
      notice.

     

     (e)           Counterparts.  This
      Agreement may be executed in counterparts, each of which shall be deemed an
      original and all of which together shall constitute one instrument.

     

    

     

    [Signature
      Page Follows]

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    The
      parties have executed this Common Stock Purchase Agreement as of the date first
      set forth above.

     

    COMPANY:

     

    CYTORI
      THERAPEUTICS, INC.

     

    By:
      /s/ Christopher J. Calhoun

     

    Title:
      CEO

     

    Address:

    3020
      Callan Road

    San
      Diego, CA 92121

     

    Fax:  US
      858-458-0994

     

     

    PURCHASER:

     

    GREEN
      HOSPITAL SUPPLY, INC.

     

    By:
      Kunishisa Furukawa

     

    Title:
      President

     

    Address:

    3-20-8
      Kasuga Suita-City

    Osaka
      565-0853, Japan

    

    

    
      
         

      

      
        9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]